Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats

Yoshinori Itoh, Toshiaki Sendo, Toshio Hirakawa, Shinya Takasaki, Takeshi Goromaru, Hitoo Nakano, Ryozo Oishi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial oxygen pressure (PaO 2). The paclitaxel-induced protein extravasation was inhibited by low doses (0.1-1 mg/kg) of pemirolast or high doses (30-100 mg/kg) of cromoglycate. However, ketotifen was not effective. The decrease in PaO 2 induced by paclitaxel was also significantly reversed by pemirolast. On the other hand, the paclitaxel-induced plasma extravasation was not attenuated by a histamine H1 blocker diphenhydramine or an H 2 blocker famotidine, but was significantly reduced by a neurokinin NK1 antagonist LY303870 (0.5 mg/kg) and an NK2 antagonist SR48968 (1 mg/kg). The concentrations of proteins and sensory peptides such as substance P, neurokinin A and calcitonin gene-related peptide but not histamine in the rat bronchoalveolar lavage fluid were elevated by paclitaxel injection. Both cromoglycate and pemirolast reduced the paclitaxel-induced rise in proteins and sensory peptides. Therefore, we demonstrated for the first time that sensory nerve peptides are involved in paclitaxel hypersensitivity and that an anti-allergic agent pemirolast attenuates the paclitaxel response by inhibiting the release of sensory nerve peptides.

Original languageEnglish
Pages (from-to)888-894
Number of pages7
JournalNeuropharmacology
Volume46
Issue number6
DOIs
Publication statusPublished - May 2004
Externally publishedYes

Fingerprint

pemirolast
Paclitaxel
Neuropeptides
Hypersensitivity
Anti-Allergic Agents
Cromolyn Sodium
Peptides
1-(N-(2-methoxybenzyl)acetylamino)-3-(1H-indol-3-yl)-2-(N-(2-(4-(piperidin-1-yl)piperidin-1-yl)acetyl)amino)propane
Ketotifen
Histamine H1 Antagonists
Famotidine
Neurokinin A
Diphenhydramine
Proteins
Calcitonin Gene-Related Peptide
Partial Pressure
Bronchoalveolar Lavage Fluid

Keywords

  • Hypersensitivity
  • Paclitaxel
  • Pemirolast
  • Pulmonary dysfunction
  • Sensory nerve peptides

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. / Itoh, Yoshinori; Sendo, Toshiaki; Hirakawa, Toshio; Takasaki, Shinya; Goromaru, Takeshi; Nakano, Hitoo; Oishi, Ryozo.

In: Neuropharmacology, Vol. 46, No. 6, 05.2004, p. 888-894.

Research output: Contribution to journalArticle

Itoh, Yoshinori ; Sendo, Toshiaki ; Hirakawa, Toshio ; Takasaki, Shinya ; Goromaru, Takeshi ; Nakano, Hitoo ; Oishi, Ryozo. / Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. In: Neuropharmacology. 2004 ; Vol. 46, No. 6. pp. 888-894.
@article{81c1f9dad7e74c89bd03545d41870615,
title = "Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats",
abstract = "The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial oxygen pressure (PaO 2). The paclitaxel-induced protein extravasation was inhibited by low doses (0.1-1 mg/kg) of pemirolast or high doses (30-100 mg/kg) of cromoglycate. However, ketotifen was not effective. The decrease in PaO 2 induced by paclitaxel was also significantly reversed by pemirolast. On the other hand, the paclitaxel-induced plasma extravasation was not attenuated by a histamine H1 blocker diphenhydramine or an H 2 blocker famotidine, but was significantly reduced by a neurokinin NK1 antagonist LY303870 (0.5 mg/kg) and an NK2 antagonist SR48968 (1 mg/kg). The concentrations of proteins and sensory peptides such as substance P, neurokinin A and calcitonin gene-related peptide but not histamine in the rat bronchoalveolar lavage fluid were elevated by paclitaxel injection. Both cromoglycate and pemirolast reduced the paclitaxel-induced rise in proteins and sensory peptides. Therefore, we demonstrated for the first time that sensory nerve peptides are involved in paclitaxel hypersensitivity and that an anti-allergic agent pemirolast attenuates the paclitaxel response by inhibiting the release of sensory nerve peptides.",
keywords = "Hypersensitivity, Paclitaxel, Pemirolast, Pulmonary dysfunction, Sensory nerve peptides",
author = "Yoshinori Itoh and Toshiaki Sendo and Toshio Hirakawa and Shinya Takasaki and Takeshi Goromaru and Hitoo Nakano and Ryozo Oishi",
year = "2004",
month = "5",
doi = "10.1016/j.neuropharm.2003.11.018",
language = "English",
volume = "46",
pages = "888--894",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats

AU - Itoh, Yoshinori

AU - Sendo, Toshiaki

AU - Hirakawa, Toshio

AU - Takasaki, Shinya

AU - Goromaru, Takeshi

AU - Nakano, Hitoo

AU - Oishi, Ryozo

PY - 2004/5

Y1 - 2004/5

N2 - The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial oxygen pressure (PaO 2). The paclitaxel-induced protein extravasation was inhibited by low doses (0.1-1 mg/kg) of pemirolast or high doses (30-100 mg/kg) of cromoglycate. However, ketotifen was not effective. The decrease in PaO 2 induced by paclitaxel was also significantly reversed by pemirolast. On the other hand, the paclitaxel-induced plasma extravasation was not attenuated by a histamine H1 blocker diphenhydramine or an H 2 blocker famotidine, but was significantly reduced by a neurokinin NK1 antagonist LY303870 (0.5 mg/kg) and an NK2 antagonist SR48968 (1 mg/kg). The concentrations of proteins and sensory peptides such as substance P, neurokinin A and calcitonin gene-related peptide but not histamine in the rat bronchoalveolar lavage fluid were elevated by paclitaxel injection. Both cromoglycate and pemirolast reduced the paclitaxel-induced rise in proteins and sensory peptides. Therefore, we demonstrated for the first time that sensory nerve peptides are involved in paclitaxel hypersensitivity and that an anti-allergic agent pemirolast attenuates the paclitaxel response by inhibiting the release of sensory nerve peptides.

AB - The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial oxygen pressure (PaO 2). The paclitaxel-induced protein extravasation was inhibited by low doses (0.1-1 mg/kg) of pemirolast or high doses (30-100 mg/kg) of cromoglycate. However, ketotifen was not effective. The decrease in PaO 2 induced by paclitaxel was also significantly reversed by pemirolast. On the other hand, the paclitaxel-induced plasma extravasation was not attenuated by a histamine H1 blocker diphenhydramine or an H 2 blocker famotidine, but was significantly reduced by a neurokinin NK1 antagonist LY303870 (0.5 mg/kg) and an NK2 antagonist SR48968 (1 mg/kg). The concentrations of proteins and sensory peptides such as substance P, neurokinin A and calcitonin gene-related peptide but not histamine in the rat bronchoalveolar lavage fluid were elevated by paclitaxel injection. Both cromoglycate and pemirolast reduced the paclitaxel-induced rise in proteins and sensory peptides. Therefore, we demonstrated for the first time that sensory nerve peptides are involved in paclitaxel hypersensitivity and that an anti-allergic agent pemirolast attenuates the paclitaxel response by inhibiting the release of sensory nerve peptides.

KW - Hypersensitivity

KW - Paclitaxel

KW - Pemirolast

KW - Pulmonary dysfunction

KW - Sensory nerve peptides

UR - http://www.scopus.com/inward/record.url?scp=1642291725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642291725&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2003.11.018

DO - 10.1016/j.neuropharm.2003.11.018

M3 - Article

C2 - 15033348

AN - SCOPUS:1642291725

VL - 46

SP - 888

EP - 894

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 6

ER -